A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, \>/= 18 years of age
Locally recurrent or metastatic Her2-negative breast cancer
Locally recurrent disease must not be amenable to radiation therapy or resection with curative intent
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Prior Adjuvant chemotherapy allowed; if taxane-based a disease-free interval after completion of \>/=12 months is required
Adequate haematological, renal and liver function
You may not be if
Previous chemotherapy for locally recurrent or metastatic disease
Radiation therapy for metastatic disease (except for relief of metastatic bone pain with irradiation of \</= 30% of marrow-bearing bone)
CNS metastases
Pre-existing peripheral neuropathy
Clinically significant cardiovascular disease
Clareo Health | A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)
